These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 36557516)

  • 1. Recent Trends and Opportunities for the Targeted Immuno-Nanomaterials for Cancer Theranostics Applications.
    John C; Jain K; Masanam HB; Narasimhan AK; Natarajan A
    Micromachines (Basel); 2022 Dec; 13(12):. PubMed ID: 36557516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies.
    Nielsen TJ; Ring BZ; Seitz RS; Hout DR; Schweitzer BL
    Heliyon; 2021 Mar; 7(3):e06438. PubMed ID: 33748492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microfluidic technologies for immunotherapy studies on solid tumours.
    Paterson K; Zanivan S; Glasspool R; Coffelt SB; Zagnoni M
    Lab Chip; 2021 Jun; 21(12):2306-2329. PubMed ID: 34085677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?
    Yuan CS; Deng ZW; Qin D; Mu YZ; Chen XG; Liu Y
    Acta Biomater; 2021 Apr; 125():1-28. PubMed ID: 33639310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy discovery on tumor organoid-on-a-chip platforms that recapitulate the tumor microenvironment.
    Zhang J; Tavakoli H; Ma L; Li X; Han L; Li X
    Adv Drug Deliv Rev; 2022 Aug; 187():114365. PubMed ID: 35667465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advances in Engineered Polymer Nanoparticle Tracking Platforms towards Cancer Immunotherapy-Current Status and Future Perspectives.
    Thangam R; Patel KD; Kang H; Paulmurugan R
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Microenvironment-Specific Functional Nanomaterials for Biomedical Applications.
    Zhao L; Liu H; Xing Y; Wang R; Cheng Z; Lv C; Lv Z; Yu F
    J Biomed Nanotechnol; 2020 Sep; 16(9):1325-1358. PubMed ID: 33419489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Immuno-oncology Targets and Resistance Mechanisms.
    Tokaz MC; Baik CS; Houghton AM; Tseng D
    Curr Treat Options Oncol; 2022 Sep; 23(9):1201-1218. PubMed ID: 35980521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
    Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
    Front Immunol; 2020; 11():784. PubMed ID: 32457745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
    Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
    Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-Oncology: Emerging Targets and Combination Therapies.
    Marshall HT; Djamgoz MBA
    Front Oncol; 2018; 8():315. PubMed ID: 30191140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
    Chyuan IT; Chu CL; Hsu PN
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
    Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
    J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies.
    Dey S; Trau M; Koo KM
    Nanomaterials (Basel); 2020 Jun; 10(6):. PubMed ID: 32545182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy.
    Wei G; Zhang H; Zhao H; Wang J; Wu N; Li L; Wu J; Zhang D
    Cancer Lett; 2021 Jul; 511():68-76. PubMed ID: 33957184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation.
    Wu M; Huang Q; Xie Y; Wu X; Ma H; Zhang Y; Xia Y
    J Hematol Oncol; 2022 Mar; 15(1):24. PubMed ID: 35279217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of cancer-immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy.
    Yang J; Zhang C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 Jul; 12(4):e1612. PubMed ID: 32114718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing Skin Cancer Immunotheranostics and Precision Medicine through Functionalized Nanomodulators and Nanosensors: Recent Development and Prospects.
    Farhana A
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.